Home > Metalor > News > Metalor Technologies SA to invest in pharma

 

Metalor Technologies SA to invest in pharma

Division : Corporate

Metalor Technologies SA to invest in a new Carboplatin production line NEUCHATEL, July 5, 2004. Metalor Technologies SA announces approval by its board of directors, for a new investment in a Carboplatin production line. Through this new business development Metalor Technologies SA extends its core competency in precious metal chemistry to the pharmaceutical area. The production line will be installed in a dedicated area of the Neuchâtel plant. Thanks to this new product line we will be able to support and respond to several requests of generic pharmaceuticals companies willing to develop their activities in the oncology segment. The production of the Active Pharmaceutical Ingredient with EP and USP grade will be conducted under strict cGMP compliance and the product will also be made available in sterile form. We expect to be fully operational by quarter 4, 2005. A venture division will be created with the name of “Metalor Pharma” and will focus its activity on the development of all application of precious metals in the healthcare industry. A team of highly qualified pharmaceutical experts has been put in place with the challenge to make this activity become live. Metalor Technologies SA, a key global player in the fields of precious metals, with headquarters in Neuchâtel, Switzerland is a privately owned company active on a worldwide basis in the production and sales of pure precious metals, dental health, electrotechnics, advanced coating, watch and jewellery. Metalor Technologies SA has a net income of CHF 270 Mio and employs more than 1’300 employees worldwide.

Back to archive list